Business Wire

HELLENiQ ENERGY and Chevron Sign Offshore Concession Agreements for Hydrocarbon Exploration and Production with the Hellenic Republic

16.2.2026 19:07:00 CET | Business Wire | Press Release

Share

HELLENiQ ENERGY, in collaboration with Chevron, signed today the Lease Agreements with the Hellenic Republic for the exploration of four offshore blocks located south of Crete and the Peloponnese, marking a significant milestone for Greece’s upstream development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216381183/en/

Snapshot from the signing of the lease agreements at the Maximos Mansion, attended by Prime Minister Kyriakos Mitsotakis. From left: Stavros Papastavrou, Minister of Environment and Energy; Andreas Shiamishis, CEO of HELLENiQ ENERGY; Gavin Lewis, VP Global New Ventures at Chevron; and Aristofanis Stefatos, CEO of HEREMA

The successful consortium, with Chevron at 70% interest and being the Operator and HELLENiQ ENERGY at 30% interest, was selected following a competitive international tender launched by the Greek State in 2025.

The four offshore blocks - South Crete 1, South Crete 2, South of Peloponnese, and Block A2 - cover a total area of approximately 47,000 square kilometers. Under the terms of the Lease Agreements, the Joint Venture will undertake a three-phase exploration program to help assess the hydrocarbon potential of the areas.

The target areas lie in ultra-deepwater settings - some beyond 1,500 meters of sea depth - with complex geological structures.

Andreas Shiamishis, CEO of HELLENiQ ENERGY, commented:

“This new concession agreement represents a strategically important step in HELLENiQ ENERGY’s long-term growth strategy and the further diversification of our portfolio. While investing in the energy transition, we recognize that hydrocarbons will continue to play a critical role in ensuring security of supply for many years to come.

Our participation in offshore exploration reflects a value-driven approach, focused on selective investments and partnerships that combine scale, technical excellence and deep industry experience. The collaboration with Chevron, one of the world’s leading energy companies, significantly strengthens this effort and underlines the importance we place on working alongside partners with proven expertise in complex offshore environments.”

Gavin Lewis, Chevron’s Vice President, Global New Ventures, stated:

“We look forward to working with our partners HELLENiQ ENERGY and the Hellenic Republic to evaluate the hydrocarbon potential of these frontier areas. With our expertise in developing oil and gas projects worldwide, Chevron has the resources, experience, and technology to advance and unlock new energy supplies in this frontier region.”

The signing ceremony took place in Athens in the presence of the Prime Minister of Greece, Kyriakos Mitsotakis and senior representatives from the Ministry of Environment and Energy, Chevron, and HELLENiQ ENERGY.

Signatory parties were the Minister of Environment and Energy, Stavros Papastavrou and the CEO of Hellenic Hydrocarbons and Energy Resources Management company (HEREMA), Aristofanis Stefatos, representing the Greek state, while Chevron and HELLENiQ ENERGY were represented by Gavin Lewis, VP of Global New Ventures, and by Andreas Shiamishis, Group CEO, respectively.

The Lease Agreements are now subject to ratification by the Hellenic Parliament.

About HELLENiQ ENERGY

HELLENiQ ENERGY is one of the leading integrated energy companies in Southeast Europe. Established as HELLENIC PETROLEUM in 1998, with roots dating back to Greece’s first refinery in 1958, HELLENiQ ENERGY has grown to become Greece’s largest company and one of the biggest in SE Europe, by annual revenue. Vigorously pursuing an ambitious transformation strategy, it has evolved into a regional energy leader and currently has presence in 8 countries and growing international operations, with a diversified portfolio spanning across the energy value chain.

HELLENiQ ENERGY is active in the production, supply and trading of all types of energy, with an increasing focus in clean energy and renewables. Its portfolio includes refining, supply and trading of oil and petrochemical products, hydrocarbons exploration and production, as well as fuels marketing, while growing fast in the renewable energy business.

Moreover, HELLENiQ ENERGY is developing an integrated Green Utility strategic business unit, following the 100% acquisition of Elpedison – now rebranded to Enerwave, a Greek power and gas generation and supply company. This new business unit will produce and supply energy -primarily from renewables- directly to the Greek market, delivering on the Group’s commitment to a just, affordable, and secure energy transition.

Headquartered in Athens, Greece, HELLENiQ ENERGY is listed on the Athens Exchange (ticker: ELPE), with a secondary listing on the London Stock Exchange (LSE: HLPD) through Global Depository Receipts (GDRs).

www.helleniqenergy.gr

View source version on businesswire.com: https://www.businesswire.com/news/home/20260216381183/en/

Contacts

HelleniQEnergy@secnewgate.co.uk

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye